STOCK TITAN

[Form 4] Ingevity Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

J. Kevin Willis, a director of Ingevity Corp (NGVT), reported a transaction dated 10/01/2025 in which he acquired 506 shares of Common Stock at a price of $54.44 per share. The Form 4 shows the shares represent vested deferred stock units that were elected in lieu of quarterly director fees and will convert into common shares upon his termination of board service under the company plans. After the reported transaction the filing shows the reporting person beneficially owned 8,300 shares directly. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

J. Kevin Willis, un direttore di Ingevity Corp (NGVT), ha riportato una Transazione datata 10/01/2025 in cui ha acquisito 506 azioni di Common Stock al prezzo di $54.44 per azione. Il modulo 4 mostra che le azioni rappresentano unità azionarie differite vestite (vesting) che sono state elette in luogo delle commissioni trimestrali del direttore e si convertiranno in azioni ordinarie al termine del servizio in consiglio secondo i piani della società. Dopo la transazione riportata, la persona che ha presentato la dichiarazione deteneva beneficiariamente direttamente 8.300 azioni. Il modulo 4 è stato firmato da un procuratore-in-fatto il 02/10/2025.

J. Kevin Willis, un director de Ingevity Corp (NGVT), reportó una transacción fechada 10/01/2025 en la que adquirió 506 acciones de Common Stock a un precio de $54.44 por acción. El Formulario 4 muestra que las acciones representan unidades de acciones diferidas que vencen (vesting) y que fueron elegidas en lugar de las comisiones trimestrales de director, y se convertirán en acciones comunes al terminar su servicio en la junta de acuerdo con los planes de la empresa. Después de la transacción reportada, la persona que presenta la declaración poseía beneficiosamente directamente 8,300 acciones. El Formulario 4 fue firmado por un apoderado el 02/10/2025.

J. Kevin Willis는 Ingevity Corp(NGVT)의 이사로서, 10/01/2025로 날짜가 기록된 거래를 보고하였으며, 주당 가격 $54.44506 주의 보통주를 취득했습니다. Form 4에는 이 주식이 분기별 이사 수수료 대신 vesting된 주식단위로 선택되었고 회사의 계획에 따라 이사회 서비스 종료 시 보통주로 전환될 것임이 나타나 있습니다. 보고된 거래 이후, 신고인은 직접적으로 8,300 주의 주식을 실질적으로 소유하고 있었습니다. Form 4는 10/02/2025에 대리인에 의해 서명되었습니다.

J. Kevin Willis, un directeur de Ingevity Corp (NGVT), a signalé une transaction datée du 10/01/2025 au cours de laquelle il a acquis 506 actions ordinaires au prix de 54,44 $ par action. Le Formulaire 4 indique que les actions représentent des unités d’actions différées acquises qui ont été choisies à la place des frais trimestriels de directeur et qui se transformeront en actions ordinaires à la fin de son mandat au conseil, conformément aux plans de la société. Après la transaction signalée, la personne qui déclare détenait directement 8 300 actions. Le Formulaire 4 a été signé par un mandataire le 02/10/2025.

J. Kevin Willis, ein Direktor von Ingevity Corp (NGVT), meldete eine Transaktion mit dem Datum 10/01/2025, bei der er 506 Aktien Stammaktien zu einem Preis von $54,44 pro Aktie erworben hat. Das Formular 4 zeigt, dass die Aktien vesteten, zuteilungsbereite Einheiten waren, die anstelle der vierteljährlichen Vorstandsgebühren gewählt wurden und beim Beenden des Vorstands gemäß den Plänen des Unternehmens in Stammaktien umgewandelt werden. Nach der gemeldeten Transaktion hielt die meldende Person direkt 8.300 Aktien. Das Formular 4 wurde von einem Bevollmächtigten am 02/10/2025 unterzeichnet.

جا. كيفن ويلس، مدير في شركة إنجيفتي (Ingevity Corp) (NGVT)، أبلغ عن معاملة بتاريخ 10/01/2025 اشترى فيها 506 أسهم من الأسهم العادية بسعر $54.44 للسهم. يبيّن النموذج 4 أن الأسهم تمثل وحدات أسهم مؤجلة مكتسبة تم اختيارها بدلاً من أتعاب المدير الربعية وستتحول إلى أسهم عادية عند إنهاء خدمته في المجلس وفقاً لخطط الشركة. بعد المعاملة المشار إليها، كان للشخص المبلغ مالكاً مستفيداً مباشرة 8,300 سهم. تم توقيع النموذج 4 من قبل وكيل مفوض في 02/10/2025.

J. Kevin Willis,Ingevity Corp (NGVT)的董事,报告了一笔日期为10/01/2025的交易,他以每股价格$54.44购买了506股普通股。 Form 4显示这些股票代表已归属的递延股票单位,在替代季度董事费用的情况下被选中,并将根据公司计划在他结束董事任期时转换为普通股。 该交易后,申报人直接直接拥有8,300股受益所有权。 Form 4由授权代理人在10/02/2025签署。

Positive
  • None.
Negative
  • None.

J. Kevin Willis, un direttore di Ingevity Corp (NGVT), ha riportato una Transazione datata 10/01/2025 in cui ha acquisito 506 azioni di Common Stock al prezzo di $54.44 per azione. Il modulo 4 mostra che le azioni rappresentano unità azionarie differite vestite (vesting) che sono state elette in luogo delle commissioni trimestrali del direttore e si convertiranno in azioni ordinarie al termine del servizio in consiglio secondo i piani della società. Dopo la transazione riportata, la persona che ha presentato la dichiarazione deteneva beneficiariamente direttamente 8.300 azioni. Il modulo 4 è stato firmato da un procuratore-in-fatto il 02/10/2025.

J. Kevin Willis, un director de Ingevity Corp (NGVT), reportó una transacción fechada 10/01/2025 en la que adquirió 506 acciones de Common Stock a un precio de $54.44 por acción. El Formulario 4 muestra que las acciones representan unidades de acciones diferidas que vencen (vesting) y que fueron elegidas en lugar de las comisiones trimestrales de director, y se convertirán en acciones comunes al terminar su servicio en la junta de acuerdo con los planes de la empresa. Después de la transacción reportada, la persona que presenta la declaración poseía beneficiosamente directamente 8,300 acciones. El Formulario 4 fue firmado por un apoderado el 02/10/2025.

J. Kevin Willis는 Ingevity Corp(NGVT)의 이사로서, 10/01/2025로 날짜가 기록된 거래를 보고하였으며, 주당 가격 $54.44506 주의 보통주를 취득했습니다. Form 4에는 이 주식이 분기별 이사 수수료 대신 vesting된 주식단위로 선택되었고 회사의 계획에 따라 이사회 서비스 종료 시 보통주로 전환될 것임이 나타나 있습니다. 보고된 거래 이후, 신고인은 직접적으로 8,300 주의 주식을 실질적으로 소유하고 있었습니다. Form 4는 10/02/2025에 대리인에 의해 서명되었습니다.

J. Kevin Willis, un directeur de Ingevity Corp (NGVT), a signalé une transaction datée du 10/01/2025 au cours de laquelle il a acquis 506 actions ordinaires au prix de 54,44 $ par action. Le Formulaire 4 indique que les actions représentent des unités d’actions différées acquises qui ont été choisies à la place des frais trimestriels de directeur et qui se transformeront en actions ordinaires à la fin de son mandat au conseil, conformément aux plans de la société. Après la transaction signalée, la personne qui déclare détenait directement 8 300 actions. Le Formulaire 4 a été signé par un mandataire le 02/10/2025.

J. Kevin Willis, ein Direktor von Ingevity Corp (NGVT), meldete eine Transaktion mit dem Datum 10/01/2025, bei der er 506 Aktien Stammaktien zu einem Preis von $54,44 pro Aktie erworben hat. Das Formular 4 zeigt, dass die Aktien vesteten, zuteilungsbereite Einheiten waren, die anstelle der vierteljährlichen Vorstandsgebühren gewählt wurden und beim Beenden des Vorstands gemäß den Plänen des Unternehmens in Stammaktien umgewandelt werden. Nach der gemeldeten Transaktion hielt die meldende Person direkt 8.300 Aktien. Das Formular 4 wurde von einem Bevollmächtigten am 02/10/2025 unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
WILLIS J KEVIN

(Last) (First) (Middle)
C/O INGEVITY CORPORATION
4920 O'HEAR AVE, SUITE 400

(Street)
NORTH CHARLESTON SC 29405

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Ingevity Corp [ NGVT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 A 506(1) A $54.44 8,300 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents vested deferred stock units (DSUs) granted pursuant to the reporting person's election to receive DSUs in lieu of quarterly director fees. These DSUs will settle into an equal number of shares of the Company's Common Stock upon the reporting person's termination of board service pursuant to the Company's Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Remarks:
J. Kevin Willis By: Mavis Huger as Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Ingevity director J. Kevin Willis report on Form 4 (NGVT)?

The Form 4 reports an acquisition of 506 shares of Common Stock on 10/01/2025 at $54.44 per share.

Why were the 506 shares issued to J. Kevin Willis?

The filing states the shares represent vested deferred stock units (DSUs) elected in lieu of quarterly director fees and will settle into shares upon termination of board service.

How many shares does J. Kevin Willis beneficially own after the transaction?

The Form 4 reports 8,300 shares beneficially owned following the reported transaction.

When was the Form 4 signed and who signed it?

The Form 4 is dated and signed by Mavis Huger as attorney-in-fact for J. Kevin Willis on 10/02/2025.

Does the Form 4 indicate the DSUs convert immediately to shares?

No. The filing explicitly states the DSUs will settle into shares upon the reporting person’s termination of board service under the company plans.
Ingevity Corp

NYSE:NGVT

NGVT Rankings

NGVT Latest News

NGVT Latest SEC Filings

NGVT Stock Data

1.95B
35.99M
1.21%
103.73%
2.04%
Specialty Chemicals
Chemicals & Allied Products
Link
United States
NORTH CHARLESTON